Bafisontamab
As of the edition of 20 October 2026, Bafisontamab is an antibody: in active development; acts on EGFR and MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 5, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Chemically induced; Digestive system; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 3 | 0 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| EpimAb Biotherapeutics | Lead sponsor of trials | 2018 to now |
| Rose Research Center | Lead sponsor of trials | 2021 to now |